Gleevec drug benefit and side effects, for GIST
Gleevec, a once-a-day
that has helped boost the survival rate for some
leukemia patients, lowers the
risk that a rare stomach
cancer will come back by 70 percent. The National
Institutes of Health-funded team found that 97 per cent of patients with a
stomach cancer called gastrointestinal stromal tumor or GIST who took Gleevec
for one year remained cancer-free after surgery as compared to 83 percent of
patients given a placebo.
Gleevec drug, made by Novartis under the generic name imatinib, was approved in 2002 for patients with chronic myeloid leukemia. Gleevec is also approved for GIST, but the government-funded study means it could work as a front-line treatment right after patients get the tumor surgically removed. Conventional chemotherapy agents have been notoriously ineffective in GIST. This study for the first time demonstrated that targeted molecular therapy reduces the rate of recurrence after complete removal of a primary GIST. Researchers tested more than 600 patients for the study, which lasted from 2002 until April 2007. Patients who were given placebos will now be offered Gleevec, too. "Gleevec was one of the first targeted therapies that showed remarkable efficacy in clinical trials," said Dr. John Niederhuber, head of the National Cancer Institute, which paid for the study. The American Cancer Society says it is not known how many new gastrointestinal stromal tumors are diagnosed each year but estimated that around 1,500 malignant cases occur in the United States. Novartis estimated that 5,000 to 6,000 U.S. cases, benign and malignant, occur each year. "We will now work with the investigators on a submission to gain regulatory approval for Gleevec as adjuvant treatment for GIST," said Dr. Diane Young, head of global medical affairs at Novartis.